Literature DB >> 22340588

The RAF inhibitor paradox revisited.

Adrienne D Cox1, Channing J Der.   

Abstract

The success of the RAF protein kinase inhibitor vemurafenib for the treatment of BRAF mutant metastatic melanoma has produced another poster child for the promise of personalized medicine. However, the results of a recent study also reveal unexpected pitfalls in the application of signal transduction-targeted therapies. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 22340588      PMCID： PMC3285264          DOI： 10.1016/j.ccr.2012.01.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.

Authors:  Patrick A Oberholzer; Damien Kee; Piotr Dziunycz; Antje Sucker; Nyam Kamsukom; Robert Jones; Christine Roden; Clinton J Chalk; Kristin Ardlie; Emanuele Palescandolo; Adriano Piris; Laura E MacConaill; Caroline Robert; Günther F L Hofbauer; Grant A McArthur; Dirk Schadendorf; Levi A Garraway
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

3.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Authors:  Ramin Nazarian; Hubing Shi; Qi Wang; Xiangju Kong; Richard C Koya; Hane Lee; Zugen Chen; Mi-Kyung Lee; Narsis Attar; Hooman Sazegar; Thinle Chodon; Stanley F Nelson; Grant McArthur; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

4.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Authors:  Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J Brandhuber; Daniel J Anderson; Ryan Alvarado; Mary J C Ludlam; David Stokoe; Susan L Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P Hoeflich; Bijay S Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S Friedman; Shiva Malek
Journal:  Nature       Date:  2010-02-03       Impact factor: 49.962

5.  Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Authors:  Sonja J Heidorn; Carla Milagre; Steven Whittaker; Arnaud Nourry; Ion Niculescu-Duvas; Nathalie Dhomen; Jahan Hussain; Jorge S Reis-Filho; Caroline J Springer; Catrin Pritchard; Richard Marais
Journal:  Cell       Date:  2010-01-22       Impact factor: 41.582

6.  Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas.

Authors:  A Balmain; M Ramsden; G T Bowden; J Smith
Journal:  Nature       Date:  1984 Feb 16-22       Impact factor: 49.962

7.  H-ras activation in benign and self-regressing skin tumors (keratoacanthomas) in both humans and an animal model system.

Authors:  J Leon; H Kamino; J J Steinberg; A Pellicer
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

8.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Authors:  Fei Su; Amaya Viros; Carla Milagre; Kerstin Trunzer; Gideon Bollag; Olivia Spleiss; Jorge S Reis-Filho; Xiangju Kong; Richard C Koya; Keith T Flaherty; Paul B Chapman; Min Jung Kim; Robert Hayward; Matthew Martin; Hong Yang; Qiongqing Wang; Holly Hilton; Julie S Hang; Johannes Noe; Maryou Lambros; Felipe Geyer; Nathalie Dhomen; Ion Niculescu-Duvaz; Alfonso Zambon; Dan Niculescu-Duvaz; Natasha Preece; Lídia Robert; Nicholas J Otte; Stephen Mok; Damien Kee; Yan Ma; Chao Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Hoa Nguyen; Mark Kockx; Luc Andries; Brian Lestini; Keith B Nolop; Richard J Lee; Andrew K Joe; James L Troy; Rene Gonzalez; Thomas E Hutson; Igor Puzanov; Bartosz Chmielowski; Caroline J Springer; Grant A McArthur; Jeffrey A Sosman; Roger S Lo; Antoni Ribas; Richard Marais
Journal:  N Engl J Med       Date:  2012-01-19       Impact factor: 91.245

9.  RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Authors:  Poulikos I Poulikakos; Chao Zhang; Gideon Bollag; Kevan M Shokat; Neal Rosen
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

10.  COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Authors:  Cory M Johannessen; Jesse S Boehm; So Young Kim; Sapana R Thomas; Leslie Wardwell; Laura A Johnson; Caroline M Emery; Nicolas Stransky; Alexandria P Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R Murray; Kourosh Salehi-Ashtiani; David E Hill; Marc Vidal; Jean J Zhao; Xiaoping Yang; Ozan Alkan; Sungjoon Kim; Jennifer L Harris; Christopher J Wilson; Vic E Myer; Peter M Finan; David E Root; Thomas M Roberts; Todd Golub; Keith T Flaherty; Reinhard Dummer; Barbara L Weber; William R Sellers; Robert Schlegel; Jennifer A Wargo; William C Hahn; Levi A Garraway
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962
  10 in total
  9 in total

1.  The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies.

Authors:  Mahamat Babagana; Julia V Kichina; Hannah Slabodkin; Sydney Johnson; Alexei Maslov; Lorin Brown; Kristopher Attwood; Mikhail A Nikiforov; Eugene S Kandel
Journal:  Mol Carcinog       Date:  2019-09-30       Impact factor: 4.784

2.  Toward personalized cancer nanomedicine - past, present, and future.

Authors:  Alexander H Stegh
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

3.  Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities.

Authors:  Marcus R Kelly; Kaja Kostyrko; Kyuho Han; Nancie A Mooney; Edwin E Jeng; Kaitlyn Spees; Phuong T Dinh; Keene L Abbott; Dana M Gwinn; E Alejandro Sweet-Cordero; Michael C Bassik; Peter K Jackson
Journal:  Cancer Discov       Date:  2020-07-29       Impact factor: 38.272

Review 4.  Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.

Authors:  Markus Morkel; Pamela Riemer; Hendrik Bläker; Christine Sers
Journal:  Oncotarget       Date:  2015-08-28

5.  Distribution bias analysis of germline and somatic single-nucleotide variations that impact protein functional site and neighboring amino acids.

Authors:  Yang Pan; Cheng Yan; Yu Hu; Yu Fan; Qing Pan; Quan Wan; John Torcivia-Rodriguez; Raja Mazumder
Journal:  Sci Rep       Date:  2017-02-08       Impact factor: 4.379

6.  Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.

Authors:  Rand Arafeh; Karen Flores; Alona Keren-Paz; Galia Maik-Rachline; Naomi Gutkind; Steven Rosenberg; Rony Seger; Yardena Samuels
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

7.  CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.

Authors:  Michal Alon; Rand Arafeh; Joo Sang Lee; Sanna Madan; Shelly Kalaora; Adi Nagler; Tereza Abgarian; Polina Greenberg; Eytan Ruppin; Yardena Samuels
Journal:  Oncotarget       Date:  2018-07-27

8.  Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling.

Authors:  Jeffrey R Whiteaker; Kanika Sharma; Melissa A Hoffman; Eric Kuhn; Lei Zhao; Alexandra R Cocco; Regine M Schoenherr; Jacob J Kennedy; Ulianna Voytovich; Chenwei Lin; Bin Fang; Kiah Bowers; Gordon Whiteley; Simona Colantonio; William Bocik; Rhonda Roberts; Tara Hiltke; Emily Boja; Henry Rodriguez; Frank McCormick; Matthew Holderfield; Steven A Carr; John M Koomen; Amanda G Paulovich
Journal:  Cell Rep Methods       Date:  2021-06-14

9.  A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner.

Authors:  Selina K Sutton; Daniel R Carter; Patrick Kim; Owen Tan; Greg M Arndt; Xu Dong Zhang; Jonathan Baell; Benjamin D Noll; Shudong Wang; Naresh Kumar; Grant A McArthur; Belamy B Cheung; Glenn M Marshall
Journal:  Oncotarget       Date:  2016-08-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.